| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
ALCAM (CD166) is known as a marker that is highly expressed in cancer stem cells (CSCs) and mesenchymal stem cells (MSCs) of human and mice. In this study, we additionally found that ALCAM is highly expressed in immunosuppressors such as Tregs and MDSCs as well as MSCs. We conducted comprehensive research in vitro and in vivo, and revealed that ALCAM plays a functional role not only in immunosuppressive activity of these immunosuppressors on induction of tumor-specific CTLs, but also in stemness including self-renewability and chemoresistance of CSCs and MSCs, and that blocking ALCAM successfully induces anti-tumor immunity enough for eliminating tumors by abrogating the cancer-caused immune dysfunction in murine tumor models. Thus, targeting ALCAM may be a distinct and promising strategy for treating cancer by simultaneously reprogramming both tumor malignancy and abnormal immunity in clinical settings.
|
